GSK acquires RAPT Therapeutics

GSK has announced its agreement to acquire RAPT Therapeutics for $2.2 billion, expanding its portfolio in the biopharmaceutical sector. This acquisition provides GSK access to RAPT's development pipeline, notably including ozureprubart, an investigational monoclonal antibody intended to prevent food allergies, which is currently in Phase IIb of clinical trials. This move underscores GSK's strategy to bolster its innovative drug offerings, particularly in allergy treatment.

The deal stipulates that GSK will purchase RAPT Therapeutics shares at $58.00 each, culminating in an estimated equity value of $2.2 billion. After adjusting for cash assets, GSK forecasts an upfront expenditure of approximately $1.9 billion. The acquisition bestows upon GSK the worldwide rights to the ozureprubart program, with exceptions for Mainland China, Macau, Taiwan, and Hong Kong. GSK will also manage the milestone and royalty obligations attributed to RAPT's partner, Shanghai Jeyou Pharmaceutical Co. The transaction is slated to conclude in the first quarter of 2026.

The acquisition enhances GSK's strategic focus within the immune disorder field. By integrating ozureprubart into its pipeline, GSK aims to leverage the monoclonal antibody's potential to meet growing demand for effective allergen prophylactics. The alignment fits with GSK's commitment to bringing forward therapies that address significant unmet medical needs, particularly in immunology and inflammation.

In the context of the biopharmaceutical sector, GSK's acquisition of RAPT Therapeutics highlights a competitive push toward expansion and consolidation. As demand for advanced therapeutic solutions increases, companies are increasingly investing in emerging technologies and promising clinical candidates. This transaction signals GSK's response to competitive pressures and its intent to fortify its position in the market against rival firms advancing similar treatments.

As the deal progresses toward closure, regulatory clearances and integration planning will be critical next steps. Attention will also be on GSK's ability to progress ozureprubart through the remaining stages of clinical development and navigate the complex landscape of market authorizations. The closing process, set for early 2026, will be pivotal in determining the ultimate impact of this acquisition on GSK's long-term growth trajectory.